SCHEMBL30258709

SCHEMBL30258709

CCc1ccc2oc(CC)c(C(=O)c3cc(Br)c(O)c(Br)c3)c2c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 10/20 0.80
EYA3 Q99504 5/20 0.80
TTR P02766 6/20 0.73
CYP2C19 P33261 5/20 0.73
CYP2C9 P11712 3/20 0.73
MEN1 O00255 2/20 0.73
ABCB11 O95342 2/20 0.73
LMNA P02545 2/20 0.73
PGR P06401 2/20 0.73
ADRA2A P08913 2/20 0.73
TBXA2R P21731 2/20 0.73
OPRM1 P35372 2/20 0.73
SLC6A3 Q01959 2/20 0.73
KMT2A Q03164 2/20 0.73
NR1H4 Q96RI1 2/20 0.73
EYA2 O00167 1/20 0.73
ABCC4 O15439 1/20 0.73
PLIN1 O60240 1/20 0.73
NR1I2 O75469 1/20 0.73
USP2 O75604 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30258768 0.90 SLC22A12 (0.80) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL1287499 0.89 SLC22A12 (1.00) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL30357377 0.89 SLC22A12 (0.81) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL30258695 0.88 SLC22A12 (0.80) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL1287381 0.86 SLC22A12 (0.78) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL30357412 0.86 SLC22A12 (0.78) SLC22A12EYA3TTRCYP2C19CYP2C9
SCHEMBL6336510 0.86 SLC22A12 (0.78) SLC22A12EYA3TTRCYP2C19CYP2C9
Benzbromarone SCHEMBL19205474 0.85 SLC22A12 (1.00) SLC22A12EYA3TTRCYP2C19CYP2C9
Benzbromarone SCHEMBL48993 0.85 SLC22A12 (1.00) SLC22A12EYA3TTRCYP2C19CYP2C9
Benzbromarone SCHEMBL29361528 0.85 SLC22A12 (1.00) SLC22A12EYA3TTRCYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF INNOVO THERAPEUTICS INC. (KR) 2025-09-11 US claimed
EP-4413981-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Innovo Therapeutics Inc. (KR) 2024-08-14 EP claimed
CN-118043043-A Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof 因诺沃治疗有限公司 2024-05-14 CN claimed
WO-2023059121-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)이노보테라퓨틱스 2023-04-13 WO claimed
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF INNOVO THERAPEUTICS INC. (KR) 2025-09-11 US disclosed
EP-4413981-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Innovo Therapeutics Inc. (KR) 2024-08-14 EP disclosed
CN-118043043-A Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof 因诺沃治疗有限公司 2024-05-14 CN disclosed
WO-2023059121-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)이노보테라퓨틱스 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HSPH1, HSP90AA1, HSPD1 SLC22A12 815/4885EYA3 1904/4885TTR 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.